Medincell: Videoconference and Publication of Half-year Financial Results, Tuesday, December 10th, 2024
29 11월 2024 - 2:40AM
Business Wire
Regulatory News:
Medincell (Paris:MEDCL) will hold a videoconference on
Tuesday December 10th, 2024 to present the half-year financial
results (April 2024-September 2024)
> Meeting in French, 6:00 pm (CET):
https://www.medincell.com/fr/live-fr/
> Meeting in English, 7:00 pm (CET):
https://www.medincell.com/live-en/
Shareholders are invited to send their questions to
communication@medincell.com, or through the chat system during the
videoconference.
About Medincell
Medincell is a clinical- and commercial-stage biopharmaceutical
licensing company developing long-acting injectable drugs in many
therapeutic areas. Our innovative treatments aim to guarantee
compliance with medical prescriptions, to improve the effectiveness
and accessibility of medicines, and to reduce their environmental
footprint. They combine active pharmaceutical ingredients with our
proprietary BEPO® technology which controls the delivery of a drug
at a therapeutic level for several days, weeks or months from the
subcutaneous or local injection of a simple deposit of a few
millimeters, entirely bioresorbable. The first treatment based on
BEPO® technology, intended for the treatment of schizophrenia, was
approved by the FDA in April 2023, and is now distributed in the
United States by Teva under the name UZEDY® (BEPO® technology is
licensed to Teva under the name SteadyTeq™). We collaborate with
leading pharmaceutical companies and foundations to improve global
health through new treatment options. Based in Montpellier,
Medincell currently employs more than 140 people representing more
than 25 different nationalities.
UZEDY® and SteadyTeq™ are trademarks of Teva Pharmaceuticals
medincell.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241128222960/en/
David Heuzé Head of Corporate and Financial
Communications, and ESG david.heuze@Medincell.com / +33 (0)6 83 25
21 86
Grace Kim Head of US Financial Strategy & IR
grace.kim@Medincell.com / +1 (646) 991-4023
Nicolas Mérigeau/ Arthur Rouillé Media Relations
Medincell@newcap.eu / +33 (0)1 44 71 94 94
Louis-Victor Delouvrier/Alban Dufumier Investor Relations
France Medincell@newcap.eu / +33 (0)1 44 71 94 94
Medincell (EU:MEDCL)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025
Medincell (EU:MEDCL)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 1월(1) 2025
